Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Autor: Meena Thayu, A. Roshak, Jose Manuel Trigo, Jong Seok Lee, Keunchil Park, Santiago Viteri, Ramaswamy Govindan, Natasha B. Leighl, Ji-Youn Han, Paul Mitchell, Nahor Haddish-Berhane, James Chih-Hsin Yang, Chee Khoon Lee, Roland Elmar Knoblauch, Patricia Lorenzini, Byoung Chul Cho, Dawn Millington, Nicolas Girard, Alexander I. Spira, Tsung-Ying Yang, Rachel E. Sanborn, Eric B. Haura, J.C. Curtin, Matthew G Krebs, Pilar Garrido, Koichi Goto, Sang-We Kim, Dong Wan Kim, Karen L. Reckamp, Ki Hyeong Lee, Joshua Bauml, Joshua K. Sabari, Catherine A. Shu, John Xie

Publikováno v: Park, K, Haura, E, Leighl, N B, Mitchell, P, Shu, C, Girard, N, Viteri, S, Han, J-Y, Kim, S-W, Lee, C K, Sabari, J, Spira, A, Yang, T-Y, Kim, D-W, Lee, K H, Sandborn, R, Trigo, J, Goto, K, Lee, J-S, Yang, J C-H, Govindan, R, Bauml, J M, Garrido, P, Krebs, M, Reckamp, K, Xie, J, Curtin, J, Haddish-Berhane, N, Roshak, A, Millington, D, Lorenzini, P, Thayu, M, Knoblauch, R & Cho, B C 2021, ' Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.21.00662

PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33e9ed2c5315a009149bf7d14f706708
https://doi.org/10.1200/jco.21.00662

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Autor: A. Roshak, Chae Won Park, Matthew V. Lorenzi, Seong Gu Heo, Min Hee Hong, Mi Ran Yun, Sun Min Lim, Soo-Hwan Lee, Meena Thayu, Kyoung Ho Pyo, Byoung Chul Cho, Seo Yoon Jeong, Hye Ryun Kim, Seok Young Kim, S.M. Lim, J.C. Curtin, Jiyeon Yun, Jae Hwan Kim, Roland Elmar Knoblauch

Publikováno v: Cancer Discovery. 10:1194-1209

EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46a6d78c9fe5fee0418366e16ac9bba4
https://doi.org/10.1158/2159-8290.cd-20-0116

OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

Autor: Matthew G Krebs, Grace Gao, S-H.I. Ou, Meena Thayu, Jose Manuel Trigo, Jonathan H. Goldman, Anna Minchom, R.W. Schnepp, Benjamin Besse, Alexander I. Spira, Aaron S. Mansfield, A. Roshak, Pasi A. Jänne, Z. Wang, Byoung Chul Cho, Z. Ma, J.C. Curtin, Chee Khoon Lee, Ravi Salgia, Roland Elmar Knoblauch

Publikováno v: Journal of Thoracic Oncology. 16:S874-S875

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ba2dc0ffde316d59d0e340d9ef2ef65
https://doi.org/10.1016/j.jtho.2021.08.084

P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

Autor: D. Pang, T. Sun, K. Patel, Nahor Haddish-Berhane, M. Martinez, Roland Elmar Knoblauch, S.M. Shreeve, A. Roshak, J. Karkera, R.B. Verheijen, Jinqiao Xie, J.C. Curtin

Publikováno v: Journal of Thoracic Oncology. 16:S620-S621

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::79c0ec99d1eb8422e782697bca45743d
https://doi.org/10.1016/j.jtho.2021.01.1130

Abstract 953: Efficacy of amivantamab, a bispecific EGFR/MET antibody, correlates with EGFR expression and signaling in NSCLC models with wild-type EGFR

Autor: Benjamin Henley, Kristen M. Chevalier, Sylvie Laquerre, Sheri Moores, Matthew V. Lorenzi, Eric B. Haura, Barbara Bushey, Smruthi Vijayaraghaven, Gerald Chu, Matthew Smith, Nataša Obermajer, J.C. Curtin, Kathryn Packman

Publikováno v: Cancer Research. 81:953-953

Small molecule EGFR inhibitors have proven effective in treatment of Non-Small Cell Lung Cancer (NSCLC) with activating EGFR mutations, however there is minimal to no efficacy in wild-type EGFR NSCLC. Amivantamab, an EGFR/MET bispecific antibody, has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::266ef128b03f7b05e25f07494efff6b3
https://doi.org/10.1158/1538-7445.am2021-953